Global Penile Cancer Market Major Players 2024, Forecast To 2033
8 Mar, 2024
The penile cancer market has witnessed robust growth, rising from $22.25 billion in 2023 to $24 billion in 2024, with a CAGR of 7.9%. This growth is attributed to factors such as early detection systems and integration of digital pathology. Looking forward, the market is forecasted to reach $31.71 billion by 2028, with a CAGR of 7.2%, driven by trends such as telemedicine and improvements in imaging technologies.
Global Penile Cancer Market Key Driver
The growth of the penile cancer market is propelled by the increasing incidence of penile cancer worldwide. Penile cancer, characterized by the development of malignant cells in the penile tissues, necessitates diagnostic, surgical, and supportive care services for effective management. According to the American Cancer Society Inc., an estimated 2,050 new cases of penile cancer and 470 deaths from the disease are expected by 2023. This rise in incidence underscores the growing demand for services related to penile cancer diagnosis and treatment, thereby driving growth in the market.
Get A Free Sample Of The Global Penile Cancer Market ReportGlobal Penile Cancer Market Segments
The penile cancer market covered in this report is segmented –
1) Type:Squamous Cell Cancer Of Penis, Aden Carcinoma Of Penis, Melanoma Of The Penis, Basal Cell Cancer Of Penis, Sarcoma Of Penis
2) Type Of Therapy:Radiation Therapy, Chemotherapy, Biological Therapy, Surgery
3) Diagnostic Test:Biopsy, Ultrasound, Imaging Tests
4) Application:Hospital, Clinics, Other Applications
By Geography: The countries covered in the penile cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the penile cancer market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the penile cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Penile Cancer Industry Players
Pfizer Inc.; Merck & Co. Inc.; Bayer AG; Bristol-Myers Squibb Company; Fresenius Kabi AG; AstraZeneca PLC; GlaxoSmithKline plc.; Takeda Pharmaceutical Company Limited; Eli Lilly and Co Ltd.; Gilead Sciences Inc.; Amgen Inc.; BioNTech SE; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Sandoz International GmbH; Eisai Co. Ltd.; Sun Pharmaceutical Industries Ltd; Ipsen S.A; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Limited; Cipla Inc.; Hikma Pharmaceuticals PLC; Lupin Limited; Glenmark Pharmaceuticals Ltd.; Natco Pharma Limited; Celon Laboratories Ltd.; Meda Pharmaceuticals; Actiza Pharmaceutical Private Limited; Celgene Corporation
Get The Full Global Penile Cancer Market Report
Penile Cancer Market Overview
Penile cancer refers to the development of malignant (cancerous) cells in the tissues of the male reproductive organ responsible for urination and sexual function. Penile cancer can originate in various parts of the penis, including the glans (head), foreskin, shaft, or other areas.